Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cost effectiveness of antituberculosis interventions.

A Castelo1, P A Mathiasi, R Iunes

  • 1Universidade Federal de Sao Paulo, Brazil.

Pharmacoeconomics
|October 5, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relationship between T90 and systemic hypertension in patients with obstructive sleep apnea: Data from the European sleep apnea database.

European journal of internal medicine·2026
Same author

Accuracy of Truenat™ MTB Plus for the diagnosis of pulmonary TB.

IJTLD open·2025
Same author

Markers of pulmonary TB in care-seeking patients with respiratory symptoms.

Public health action·2025
Same author

Characterising the SARS-CoV-2 nucleocapsid (N) protein antibody response.

The Journal of infection·2025
Same author

Prevalence of Mycobacterium leprae and Mycobacterium lepromatosis in roadkill armadillos in Brazil.

Acta tropica·2024
Same author

Chromothripsis orchestrates leukemic transformation in blast phase MPN through targetable amplification of <i>DYRK1A</i>.

bioRxiv : the preprint server for biology·2023
Same journal

Balancing Access and Value in Multi-Indication Medicines: Implications of PD-L1 Broad Listings in Australia.

PharmacoEconomics·2026
Same journal

Applications of Structural Expert Elicitations for Economic Evaluations: A Systematic Review Update.

PharmacoEconomics·2026
Same journal

Community Pharmacist Preferences for Providing a Dose Administration Aid Service in Australia: A Discrete Choice Experiment.

PharmacoEconomics·2026
Same journal

A Critical Systematic Review of Modelling Approaches and Methodologies used in Hyperlipidaemia Economic Evaluations.

PharmacoEconomics·2026
Same journal

Deriving a Korean SF-6Dv2 Value Set Using a Discrete Choice Experiment with Duration.

PharmacoEconomics·2026
Same journal

Correction: Ten Recommendations for Modelling Cost Effectiveness of Screening: Perspectives of an International Stakeholder Group.

PharmacoEconomics·2026
See all related articles

Tuberculosis (TB) treatment is highly cost-effective, yet remains a leading cause of death globally. Prioritizing cost-effective TB control strategies is crucial for low-income countries to combat this widespread disease.

Area of Science:

  • Public Health
  • Infectious Diseases
  • Health Economics

Background:

  • Tuberculosis (TB) is a leading cause of death worldwide, particularly affecting adults aged 15-59.
  • It disproportionately impacts developing nations, causing significant mortality among women of childbearing age and a substantial societal burden.
  • Economically feasible TB control strategies are often less effective in the poorest countries, highlighting the need for careful resource allocation.

Purpose of the Study:

  • To review the effectiveness and cost-effectiveness of various TB care approaches.
  • To examine strategies applicable to low-income countries, including for HIV-infected and non-infected patients.
  • To discuss financial implications and implementation of directly observed therapy (DOT) for TB.

Main Methods:

Related Experiment Videos

  • Review of evidence on TB care effectiveness and cost-effectiveness.
  • Analysis of TB control program components: detection, treatment, and prevention (BCG vaccination, chemoprophylaxis).
  • Discussion of operational issues, financial implications, and DOT implementation.

Main Results:

  • TB treatment is the most cost-effective therapeutic program per year of life saved.
  • Adequate treatment completion is key to preventing TB spread and drug resistance.
  • Cost-effectiveness considerations are paramount for resource allocation in TB control in low and middle-income countries.

Conclusions:

  • Prioritizing patient adherence to chemotherapy is essential for effective TB control.
  • Different approaches to TB care, including DOT, require careful consideration for cost-effectiveness in resource-limited settings.
  • The roles of chemoprophylaxis and BCG vaccination in current TB control strategies warrant review.